Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
16 avr. 2024 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
05 mars 2024 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
13 févr. 2024 16h30 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
02 févr. 2024 16h15 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
18 janv. 2024 17h00 HE
|
Axogen, Inc.
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap® vs. standard-of-care neurectomy at Month 12. Axoguard Nerve...
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
04 janv. 2024 16h45 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
04 janv. 2024 16h40 HE
|
Axogen, Inc.
ALACHUA and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today...
Axogen Announces Promotions on Research and Development Team
04 janv. 2024 16h35 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve...
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
26 déc. 2023 16h15 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Axogen Announces Transition of Finance Team Leadership
06 déc. 2023 07h00 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...